Modified vaccinia ankara
- Generic Name
- Modified vaccinia ankara
- Brand Names
- Jynneos
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- TU8J357395
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.
- Associated Conditions
- Ebola Virus Disease, Monkeypox, Variola Major (Smallpox)
- Associated Therapies
- -
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and ...
Bavarian Nordic receives $63M order from BARDA to replenish bulk vaccine inventory and produce 1M freeze-dried JYNNEOS® doses for U.S. smallpox/mpox preparedness, with bulk production in 2025 and freeze-dried deliveries in 2026.
Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
Bavarian Nordic's MVA-BN vaccine approved by EMA for mpox and smallpox in adolescents 12-17 years old, following NIH-sponsored study. CEO Paul Chaplin praises EMA's expedited review. A new trial for children 2-12 years old is planned, partially funded by CEPI.
EU drug regulator approves use of Bavarian Nordic's mpox vaccine, Imvanex for adolescents
Bavarian Nordic A/S announced the European Commission's approval of Imvanex (MVA-BN) smallpox and mpox vaccine for adolescents 12-17 years old, following a CHMP recommendation. This marks the second EMA approval for MVA-BN in a younger population. A clinical study demonstrated non-inferior immune responses and similar safety profiles in adolescents and adults. Bavarian Nordic plans to extend the vaccine's indication to children 2-12 years old through an upcoming clinical trial.
Related Clinical Trials:
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
EMA approves MVA-BN for mpox and smallpox in adolescents 12-17 years, following clinical study data showing non-inferior immune responses and similar safety profiles. This marks the second EMA approval for a younger population using MVA-BN-based vaccines.
Related Clinical Trials:
Bavarian Nordic's Imvanex vaccine gets EMA nod for adolescents
EC approves Bavarian Nordic’s Imvanex for adolescents aged 12 to 17, based on CHMP recommendation and NIH-sponsored study showing non-inferior immune responses and safety profile.
ECDC Raises Mpox Risk As New Strain Emerges
ECDC raises mpox risk level to moderate following first case in Sweden, emphasizing global health interconnectedness. WHO declares mpox a global public health emergency, focusing on equitable access to diagnostics, therapies, and vaccines. Bavarian Nordic's JYNNEOS vaccine gains attention, while global collaboration and vaccination efforts are crucial, especially in Africa.
Mpox: Three ongoing vaccine trials to watch
WHO declared mpox a PHEIC in 2024, emphasizing the need for more vaccines, especially in Africa. Ongoing trials include Moderna's mRNA-1769 and BioNTech's BNT166a, both in Phase I/II. Bavarian Nordic's Jynneos is also being tested in pediatric patients in the Democratic Republic of Congo.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath